Eli Lilly and Co. stock edges higher ahead of the open after a 0.02 percent gain
Published on 09/21/2026 at 06:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Eli Lilly and Co. stock closed at USD 1,152.62 on the New York Stock Exchange on September 18, 2026, marking a modest daily gain of 0.02 percent per exchange data.
That close left the shares near recent highs and roughly in line with the broader Nasdaq move on the same day, with healthcare names contributing to the index advance.
September 18, 2026 in numbers
Eli Lilly and Co. Inc. (ISIN US5324571083, NYSE: LLY) ended the last completed US trading session on September 18, 2026 at USD 1,152.62, with intraday trading keeping the price in a tight range close to valuation levels discussed in recent analyst work.
Per data cited by MarketBeat, the stock recorded a 0.02 percent gain at the regular close on the New York Stock Exchange on September 18, 2026, with the last trade timestamped at 3:59 p.m. Eastern Time, and after-hours indications later that evening only marginally above the official close.MarketBeat
According to an overview of the session on September 18, 2026, Eli Lilly and Co. stock traded just below a quoted level of USD 1,152.93 used in several valuation discussions, underscoring that the closing price of USD 1,152.62 remained well within the narrow corridor around those fair value estimates.ad-hoc-news
The same report highlighted that, with the actual closing price at USD 1,152.62 on September 18, 2026, Eli Lilly and Co. stock traded roughly 13 percent below a consensus analyst price target of USD 1,305.25, indicating scope for further upside implied by coverage while still reflecting recent gains.ad-hoc-news
Market commentary around the same trading day pointed out that US indices such as the Nasdaq Composite posted gains on September 18, 2026, supported in part by strength in healthcare and biotechnology stocks, which helped keep Eli Lilly and Co. shares close to their recent highs.
Regulatory approval update today
Today, September 21, 2026, investor attention around Eli Lilly and Co. centers on a fresh United States Food and Drug Administration decision for one of its oncology combinations.
As Eli Lilly and Co. announced, the US FDA has granted full approval for the estrogen receptor antagonist Inluriyo (imlunestrant) in combination with the kinase inhibitor Verzenio (abemaciclib) as an all oral regimen for adults with ER positive, HER2 negative, ESR1 mutated advanced or metastatic breast cancer, based on results from the Phase 3 EMBER-3 trial.BioSpace
Coverage of notable healthcare headlines for the week noted that Eli Lilly and Co. announced the full approval on Friday, positioning the regimen as a late line treatment option for certain breast cancer patients and adding another regulatory milestone to the companys oncology portfolio ahead of todays US session.MSN
